iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. increased authorized common shares from 275,000,000 to 500,000,000; the charter amendment became effective October 16, 2026, after stockholders approved it at the October 14 annual meeting. Stockholders also approved an amendment to the 2023 Omnibus Incentive Plan. On January 1, 2027, January 1, 2028, and January 1, 2029, each annual increase to shares reserved and available for issuance equals 5% of common shares outstanding on the preceding December 31, plus 3% of shares issuable upon exercise of pre-funded warrants outstanding on that date. On January 1, 2030, January 1, 2031, January 1, 2032, and January 1, 2033, each increase equals 5% of common shares outstanding on the preceding December 31; the Board may set a lower increase before January 1 of a given year.
William Clark and Gary Sender were elected as Class III directors for terms expiring at the 2029 annual meeting. Stockholders ratified Grassi & Co., CPAs, P.C. for the fiscal year ending June 30, 2027, and approved named executive officer compensation on a non-binding advisory basis.
iBio, Inc. director Elizabeth Stoner received a grant of 38,000 stock options to buy common stock on October 14, 2026. The options have an exercise price of $0.78 per share and expire October 13, 2036. They vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to her continued service through each applicable vesting date.
iBio, Inc. director Alexandra Kropotova received a direct grant of 38,000 stock options on October 14, 2026, covering 38,000 shares of common stock at an exercise price of $0.7800 per share. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant, subject to her continued service through each applicable vesting date. They expire October 13, 2036.
iBio, Inc. director David Arkowitz was granted 38,000 stock options on October 14, 2026, covering 38,000 common shares. The options vest pro rata in monthly installments over 12 months, with the first installment vesting one month after the grant date, subject to his continued service through each applicable vesting date. The reported resulting position is 38,000 options.
iBio, Inc. director William D. Clark acquired a direct option award covering 38,000 shares on October 14, 2026, with an exercise price of $0.78 per share and an expiration date of October 13, 2036. The options vest pro rata in monthly installments over twelve months, beginning one month after the grant date, subject to his continued service through each applicable vesting date.
iBio, Inc. director Antonio Bernardino Guimaraes Parada received a direct award of 38,000 stock options on October 14, 2026. The options have an exercise price of $0.78 per share and expire October 13, 2036.
iBio, Inc. director Gary Sender received a direct award of options covering 38,000 common shares on October 14, 2026, with a $0.78-per-share exercise price. The options vest pro rata in monthly installments over twelve months, subject to continued service through each applicable vesting date, and expire October 13, 2036.
iBio, Inc. is the issuer whose common stock five reporting persons report beneficially owning: Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry each report 6,247,738 shares, or 9.72% of the class. Coastlands Capital Partners LP is identified as the direct holder; all five report shared voting and dispositive power, not sole power. Coastlands Capital LP and Coastlands Capital GP LLC are identified as the Partnership’s investment adviser and general partner, Coastlands Capital LLC as general partner of Coastlands Capital LP, and Perry as control person.
The percentage calculation uses 64,307,256 shares outstanding as of August 27, 2026. The reporting persons disclaim group membership and beneficial ownership except to the extent of each person’s pecuniary interest. The reported common-share amount excludes pre-funded warrants and warrants held by the reporting persons in excess of a 4.99% beneficial ownership limitation.
iBio, Inc. reported preclinical results from an eight-week obese non-human primate study of IBIO-610, an Activin E antibody, alone and with semaglutide. Lean mass accounted for 6% of weight lost with the combination, compared with 22% with semaglutide alone. At week 8, fat accounted for 93% and 77% of weight lost, respectively.
After a single intravenous dose, IBIO-610 showed a 97% reduction in serum levels of active Activin E at week 8 and had a 33.2-day half-life in NHPs. iBio said a projected human half-life could potentially support twice-yearly dosing and plans to begin first-in-human studies in the first half of 2027. The company noted that NHP findings may not be replicated in humans.
iBio, Inc. (IBIO) reports that it has updated its corporate presentation for use in meetings with investors, analysts and others. The updated presentation is provided as Exhibit 99.1 and is dated September 2026.
The presentation includes language identifying certain statements as forward-looking under the Private Securities Litigation Reform Act of 1995, and the company states it has no duty to update or revise the information, although it may do so through future public disclosures.